CG Oncology, Inc. (CGON)
Nasdaq · Healthcare · Biotechnology
$68.71+1.97%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.1B
- 52-week range
- $35.80 – $80.97
- 52-week change
- +77.32%
- EPS (trailing)
- −$2.75
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $4.0M (+254.70%)
- Net income
- −$161M
- Operating margin
- −4722.0%
- Diluted EPS
- −$2.08
- Free cash flow
- −$132M
From the company’s annual report on SEC EDGAR.
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Headquarters: Dallas, United States · 142 employees · cgoncology.com